Phase I, Open-label Trial to Evaluate the Safety and Immunogenicity of INO-5150 Alone or in Combination With INO-9012 in Men With Biochemically Relapsed (PSA) Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Aug 2017
At a glance
- Drugs INO 5150 (Primary) ; INO 9012
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Inovio Pharmaceuticals
- 08 Aug 2017 According to an Inovio Pharmaceuticals media release, the company expects to report data from this trial in the third quarter of 2017.
- 10 Jun 2017 Biomarkers information updated
- 06 Jun 2017 Results of preliminary analysis aseessing prostate surface antigen stabilization presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.